-
Mashup Score: 1Few Early Alzheimer's Patients Qualify for Lecanemab - 8 month(s) ago
Inclusion and exclusion criteria whittle down pool of eligible treatment candidates
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1What to Know About the Alzheimer Drug Aducanumab (Aduhelm) - 2 year(s) ago
This JAMA Internal Medicine Patient Page describes use of aducanumab for treatment of Alzheimer disease, including potential benefits, harms, and concerns about use.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
This Patient Page discusses #aducanumab, a new drug for #Alzheimerdisease. The combined results of 2 studies showed no improvement in symptoms, although plaques were reduced on brain scans. Adverse effects, such as brain swelling or bleeding, were common. https://t.co/GycMPCiv7I https://t.co/ZcMjSmhlzP
-
-
Mashup Score: 9What to Know About the Alzheimer Drug Aducanumab (Aduhelm) - 2 year(s) ago
This JAMA Internal Medicine Patient Page describes use of aducanumab for treatment of Alzheimer disease, including potential benefits, harms, and concerns about use.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
This Patient Page discusses #aducanumab, a new drug for #Alzheimerdisease. The combined results of 2 studies showed no improvement in symptoms, although plaques were reduced on brain scans. Adverse effects, such as brain swelling or bleeding, were common. https://t.co/InBSU5ea6m
-
-
Mashup Score: 0
COURSE DESCRIPTION In June, 2021, the United States Food and Drug Administration (FDA) approved aducanumab, a monoclonal antibody directed at β-amyloid aggregates, for the treatment of Alzheimer’s disease. This approval was unusual and controversial in part because the FDA’s expert advisory committee had concluded that the available evidence does not support the conclusion that aducanumab slows…
Source: learning.aan.comCategories: Latest Headlines, NeurologyTweet-
Check out the latest NeuroBytes video highlighting ethical issues related to informed consent for #aducanumab. https://t.co/4vc9b378Bl #Neurology #NeuroTwitter #Alzheimers https://t.co/ynXkNrMB0O
-
-
Mashup Score: 0
Alzheimer’s disease has long thwarted our best efforts to pinpoint its underlying causes. Now, a new study in mice suggests that ‘poisonous flowers’ bulging with cellular debris could be the root source of one hallmark of the wretched disease and a b
Source: ScienceAlertCategories: Healthcare Professionals, Latest HeadlinesTweet-
Nicely written article re: #autophagy, #amyloid, and #aducanumab . #Alzheimer #neurons https://t.co/ZI3X4W1aMd
-
-
Mashup Score: 4
The June 2022 replay of past episodes showcases a selection of interviews about the impact of the FDA’s approval of aducanumab for the treatment of Alzheimer disease (AD). This episode features illuminating conversations with Drs. Gregg Day, Ron Petersen, and Jason Karlawish on the clinical science guiding amyloid-based treatments for AD, the importance of patient participation when considering…
Source: directory.libsyn.comCategories: Latest Headlines, NeurologyTweet-
Neurology Podcast: This month's Neurology Recall features interviews about the impact of the FDA's approval of #aducanumab for the treatment of #AlzheimerDisease, from clinical, patient-centered, and business perspectives to Medicare coverage. Listen now! https://t.co/c0PRev6x6y https://t.co/Mw9cMuoypQ
-
-
Mashup Score: 1
Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need.[1][1] Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers, advocacy groups, and hospital systems…
Source: Neurology Clinical PracticeCategories: Latest Headlines, NeurologyTweet-
Practical Considerations in the Administration of #Aducanumab for the Neurologist: https://t.co/3eUpZgVyml #AlzheimerDisease #NeuroTwitter https://t.co/Ha6QylowJa
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Latest Headlines, NeurologyTweet-
In our top article from the April 7 issue, Drs. @jasonkarlawish, Gil Rabinovici, Todd Golde, & @LonSchneiderMD discuss the CMS coverage w/ evidence development for #aducanumab and what it means going forward. https://t.co/p3DhDboimq The new issue goes live tomorrow. Stay tuned! https://t.co/AkyZN8gawX
-
-
Mashup Score: 1
Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need.[1][1] Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers, advocacy groups, and hospital systems…
Source: Neurology Clinical PracticeCategories: Latest Headlines, NeurologyTweet-
Practical Considerations in the Administration of #Aducanumab for the Neurologist: https://t.co/3eUpZgVyml #Alzheimer #Neurology https://t.co/QnFHQNGeik
-
-
Mashup Score: 2Amyloid Treatments for Alzheimer Disease - 2 year(s) ago
Dr. Jason Crowell talks with Dr. Gregg Day about amyloid-targeting treatments for Alzheimer disease as well as how to navigate conversations about aducanumab with patients.
Source: directory.libsyn.comCategories: Latest Headlines, NeurologyTweet-
Neurology Podcast: In today's episode, Dr. Gregg Day provides an overview of #amyloid-targeting treatments for #AlzheimerDisease and suggestions for navigating conversations about #aducanumab with patients. Listen now! https://t.co/gb9ByFXHce #NeuroTwitter https://t.co/0ya2sWt0Oe
-
Few people with early #Alzheimers disease met eligibility criteria for the new anti-amyloid monoclonal antibody treatments #lecanemab and #aducanumab, cross-sectional data from the @MayoClinic Study of Aging showed. @MedPageNeuro @judyreports https://t.co/jgKq58KILV